According to the Center of Disease Control (CDC), sickle cell disease (SCD) affects about 100,000 Americans and is the most common inherited blood disorder. SCD can be a debilitating, life-changing diagnosis, which is why Sanguine is passionate about SCD research and making research opportunities more accessible. Sanguine has worked on over 60 sickle cell research studies including 22 in the last 2 years. We have partnered with 22 different research companies to accelerate treatment development and understanding of SCD.
Sanguine’s sickle cell community is made up of over 600 individuals all dedicated to making a difference for their condition. With our at-home preclinical studies, participating in research is more convenient than ever. Our participants enjoy their experience with their phlebotomist, and have participated in Sanguine studies an average of 5 times.
Along with being committed to advancing sickle cell research, Sanguine is also dedicated to developing resources for the SCD community and spreading awareness for the condition. Sanguine is a sponsor of the 48th Annual National Convention hosted by the Sickle Cell Disease Association of America (SCDAA) and is a proud partner of both the SCDAA and the Sickle Cell Disease Foundation of California (SCDFC).
If you are interested in learning more about sickle cell research studies you may be eligible for, please check out our website.
Related Story
